Evidence map›Paper›PMID 40529859›Full record

ArticleSmall science2025

Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.

Sohaib Mahri, Rodolfo Villa, Ya-Ping Shiau, Menghuan Tang, Kelsey Jane Racacho, Qiufang Zong, Saiful Islam Chowdhury, Tan Hua, Felipe Godinez, Andrew Birkeland and 2 more

Abstract read
In one paragraph

Article in Small science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sohaib MahriDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Rodolfo VillaDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Ya-Ping ShiauDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Menghuan TangDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Kelsey Jane RacachoDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Qiufang ZongDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Saiful Islam ChowdhuryDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Tan HuaDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.
Felipe GodinezDepartment of Radiology University of California Davis Sacramento CA 95817 USA.
Andrew BirkelandDepartment of Otolaryngology, Head and Neck Surgery University of California Davis Sacramento CA 95817 USA.
Tzu-Yin LinDivision of Hematology/Oncology Department of Internal Medicine University of California Davis Sacramento CA 95817 USA.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine UC Davis Comprehensive Cancer Center University of California Davis Sacramento CA 95817 USA.ORCID https://orcid.org/0000-0002-4015-646X

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Initiative for Maximizing Student Development at the University of California, Davis.T32GM135741 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ALDRIN V. GOMES, Manuel F Navedo · 2020 to 2026
$3.2M
Nano-Therapeutic Approaches for Oncogenic Herpesvirus-Mediated MalignanciesR01CA232845 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI IZUMIYA, YOSHIHIRO, LI, YUANPEI · 2018 to 2022
$3.2M
Tumor-penetrating nano-theranostics for image-guided interventions in spontaneous feline head and neck cancerR01DE029237 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2020 to 2024
$2.9M
A “STICK” theranostic nanoplatform for image-guided drug delivery to brain malignanciesR01EB033677 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2022 to 2025
$2.4M
Two-way Magnetic Resonance Tuning Nanoprobe Enhanced Subtraction Imaging for Precision Diagnosis of Brain MetastasisR01EB035416 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yuanpei Li · 2024 to 2026
$2.0M
Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous modelR01CA294557 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yuanpei Li · 2024 to 2026
$1.9M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA232845NCI NIH HHS R01 CA294557NIBIB NIH HHS R01 EB033677NIBIB NIH HHS R01 EB035416NIDCR NIH HHS R01 DE029237NIGMS NIH HHS T32 GM135741
6 · The paper itself

Abstract

Cancer is a daunting global health problem with a steadily rising incidence. Despite the wide arsenal of current anticancer therapies, challenges such as drug resistance, tumor heterogeneity, poor targeting, and severe side effects often lead to suboptimal efficacy and poor patient outcomes, highlighting the need for innovative therapies. Autophagy modulation has emerged as an attractive approach to complement existing therapies. The dual role of autophagy in cancer promotion and suppression has inspired the development of new drugs and therapeutic strategies focusing on both inhibition and induction. Despite the promising results of current autophagy modulators in preclinical studies, challenges such as the lack of selectivity and potency, toxicity, poor pharmacokinetics, and inadequate tumor targeting continue to limit their successful clinical translation. Many of these challenges could be overcome using nanomedicine. This review explores recent advancements in nanomedicine strategies for autophagy modulation. Successful combination strategies leveraging nanoparticles and autophagy modulators in synergy with chemotherapy, immunotherapy, phototherapy, gene therapy, and other modalities are presented. Additionally, nanomaterials with intrinsic autophagy-modulating capabilities, such as self-assembling autophagy inhibitors, are discussed. Finally, limitations of autophagy modulators currently in clinical trials are discussed, and future perspectives on designing nanomedicine for successful clinical implementation are explored.

Indexed as

autophagy inhibitionsautophagy modulationscancer therapiesclinical translationsdrug resistancesnanomedicines

Identifiers

PMID40529859
PMCPMC12168626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.